CytomX Therapeutics, Inc 10-Q for FY2026 Q3
CytomX Therapeutics, Inc. (CTMX)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
CytomX Therapeutics, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
CytomX reports Varseta-M received FDA fast track designation for relapsed/refractory metastatic colorectal cancer; expansion data showed confirmed response rates of 20% at 8.6 mg/kg and 32% at 10 mg/kg, and additional dose-selection data are expected in January of 2027. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $1.69M
- down 71.7% from $5.96M a year earlier
- Net loss
- $20M
- compared with a net loss of $14.23M a year earlier